Get the Stockscreener App
202.50
0.50%
1.01
After Hours:
204.89
2.39
+1.18%
Insulet Corporation stock is traded at $202.50, with a volume of 802.70K.
It is up +0.50% in the last 24 hours and down -7.89% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$201.49
Open:
$202.82
24h Volume:
802.70K
Relative Volume:
0.79
Market Cap:
$14.03B
Revenue:
$2.71B
Net Income/Loss:
$247.10M
P/E Ratio:
57.84
EPS:
3.5008
Net Cash Flow:
$349.90M
1W Performance:
-0.50%
1M Performance:
-7.89%
6M Performance:
-35.19%
1Y Performance:
-21.03%
1-Day Range:
$201.06
$205.67
1-Week Range:
$194.61
$205.67
52-Week Range:
$194.61
$354.88
Insulet Corporation Stock (PODD) Company Profile
Name
Insulet Corporation
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
202.50 | 13.96B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corporation Stock (PODD) Latest News
BTIG Maintains Buy Rating on Insulet (PODD) - Insider Monkey
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky - PR Newswire
Truist Cuts Price Target on Insulet to $315 From $360, Keeps Buy Rating - marketscreener.com
Insulet (PODD) down 8.2% since last earnings report: Can it rebound? - MSN
Analysts see 75% upside on Insulet Corporation (PODD) despite weak share price momentum - MSN
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - ChartMill
Evercore Reiterates Outperform Rating for Insulet Corp. (PODD) - Insider Monkey
RBC Cuts Price Target on Insulet to $325 From $380, Keeps Outperform Rating - marketscreener.com
BTIG Maintains Insulet(PODD.US) With Buy Rating, Cuts Target Price to $320 - Moomoo
BTIG Research Adjusts Insulet Price Target to $320 From $380, Maintains Buy Rating - marketscreener.com
A Look At Insulet (PODD) Valuation After Mike Panos Joins As Chief Commercial Officer - Sahm
Liquidity Mapping Around (PODD) Price Events - Stock Traders Daily
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer - MSN
Insulet Corp. stock falls to new 52-week low - MarketWatch
Insulet stock (US45784P1012): Is its tubeless insulin tech strong enough to unlock new upside? - AD HOC NEWS
New Commercial Chief and Closed-Loop Progress Might Change The Case For Investing In Insulet (PODD) - Sahm
Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth - Yahoo Finance Australia
A Look At Insulet (PODD) Valuation After Recent Share Price Weakness - Yahoo Finance
Analysts See 75% Upside on Insulet Corporation (PODD) Despite Weak Share Price Momentum - Insider Monkey
Insulet stock: What investors need to know amid diabetes tech boom - AD HOC NEWS
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet Corp. Hits 52-Week Low at USD 199.53 Amid Market Challenges - Markets Mojo
Goldman Sachs Adjusts Price Target on Insulet to $277 From $326, Maintains Buy Rating - marketscreener.com
Insulet Corporation stock hits 52-week low at 199.53 USD By Investing.com - Investing.com Australia
Insulet Corporation (PODD) Stock forecasts - Yahoo Finance UK
Insulet (PODD) Gets Downgraded by Citigroup; Price Target Lowere - GuruFocus
Insulet (PODD) Gets Downgraded by Citigroup; Price Target Lowered | PODD Stock News - GuruFocus
Insulet (PODD) Appoints Mike Panos as Chief Commercial Officer - Insider Monkey
Insulet Corporation stock hits 52-week low at 199.53 USD - Investing.com
Insulet (NASDAQ:PODD) Cut to Neutral at Citigroup - MarketBeat
Citigroup Downgrades Insulet to Neutral From Buy, Adjusts Price Target to $230 From $338 - Moomoo
Citi Downgrades Insulet Corporation (PODD) to Neutral - StreetInsider
Form DEF 14A INSULET CORP For: May 20 - StreetInsider
Robust 2025 growth, new leadership in Insulet (NASDAQ: PODD) 2026 proxy - stocktitan.net
Insulet taps into culture again and makes its ‘Scrubs’ debut - Medical Marketing and Media
Insulet recalling certain defective Omnipod insulin delivery devices - MSN
Insulet Corp. Experiences Valuation Adjustment Amidst Strong Operational Performance Metrics - Markets Mojo
Insulet announces recall of Omnipod 5 Pods due to insulin delivery issue - Top Class Actions
Evercore ISI Adjusts Insulet PT to $240 From $340, Maintains Outperform Rating - marketscreener.com
Insulet Corp. Stock Plummets to New 52-Week Low of $203.19 - Markets Mojo
Aberdeen Group plc Has $64.08 Million Stock Position in Insulet Corporation $PODD - MarketBeat
PODD PE Ratio & Valuation, Is PODD Overvalued - intellectia.ai
Insulet (PODD): 3 Reasons We Love This Stock - Yahoo Finance
Insulet (PODD) is a top-ranked growth stock: Should you buy? - MSN
Insulet Corp. Stock Hits 52-Week Low at USD 208.14 - Markets Mojo
Assessing Insulet (PODD) Valuation After Omnipod 5 Device Correction And Maintained Outlook - Sahm
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Insulet Corp (PODD) EVP receives new stock options and RSU awards - Stock Titan
Insulet Corporation Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):